3 Undervalued Pharmaceuticals Stocks for Thursday, May 02
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, May 02 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Commentary & Analysis
6 Undervalued Pharmaceuticals Stocks for Friday, February 23
Discover the top 6 undervalued Pharmaceuticals stocks for Friday, February 23 based on AAII’s Stock Grades.Jack Gilleland
3 Undervalued Pharmaceuticals Stocks for Monday, November 06
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, November 06 based on AAII’s Stock Grades.Grace Malone
6 Undervalued Pharmaceuticals Stocks for Thursday, April 27
Discover the top 6 undervalued Pharmaceuticals stocks for Thursday, April 27 based on AAII’s Stock Grades.Jenna Brashear
4 Undervalued Pharmaceuticals Stocks for Wednesday, January 18
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, January 18 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $22.0 | $618.0 | 10% |
|
| Shares Out (Mil) | 12.9 | 44.8 | 24% |
|
| Institutional Ownership | 29.9% | 85.3% | 13% |
|
| Float (Mil) | 9.1 | 47.4 | 18% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 639 | 390 | 62% |
|
| Price Change (52-week) |
59.7% | 68.6% | 82% |
|
| Growth | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.3% | 6.7% | 77% |
|
| Net Income (5yr) | 0.9% | (1.6%) | 41% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.110) | ($0.180) | $0.430 | |
| Month Ago EPS | ($0.110) | ($0.160) | $0.320 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.110) | ($0.160) | $0.320 | |
| Year/Year Chg | 120.0% | (82.6%) | (118.3%) | |
| Financials | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $46 | $291 | 19% |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 32% |
|
| EPS (TTM) | ($0.541) | ($0.700) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($6) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | $19 | $450 | 11% |
|
| Valuation | BFRI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.54 | 2.78 | 69% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BFRI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.3% | 67.0% | 88% |
|
| Net Margin | (13.8%) | (2.3%) | 19% |
|
| ROA | (28.8%) | (22.4%) | 17% |
|
| ROE | (988.4%) | (20.2%) | 0% |
|
| Liabilities to Assets | 75.2% | 32.2% | 71% |
|
| F-Score | 4 | 3 | 34% |
|
Biofrontera Inc. did not pass any screens on 8/20/2026.
